Lung NETs, unlike small-cell lung cancer (SCLC) and LCNEC, exhibit a low mutation rate, with frequent alterations in chromatin-remodeling genes and rare mutations in TP53 and RB1 (36–38). This evidence concerns the gene TP53 and lung neuroendocrine neoplasm.